This site is intended for healthcare professionals only
DiabetesontheNet Logo
Sign In / Register
News
Share this article

SMC approves two GLP-1 analogues for use in Scotland

The SMC has announced that dulaglutide and albiglutide, two once-weekly glucagon-like peptide-1 (GLP-1) receptor agonists, have been approved for use as add-on therapy in Scotland.

The SMC has announced that dulaglutide and albiglutide, two once-weekly glucagon-like peptide-1 (GLP-1) receptor agonists, have been approved for use as add-on therapy in Scotland. Both are licensed in combination with other glucose-lowering therapies, including insulin, when these fail to achieve adequate glycaemic control in conjunction with diet and exercise.

Dulaglutide 1.5mg (Trulicity®; Eli Lilly and Company) is approved as part of triple therapy in people with inadequate glycaemic control on two oral anti-diabetic drugs, as an alternative GLP-1 receptor agonist option. The SMC has not reviewed the agent for its other indication – as monotherapy in people for whom metformin is contraindicated – and currently does not recommend it for this use.

Albiglutide (Eperzan®; GlaxoSmithKline) is approved as an alternative once-weekly GLP-1 receptor agonist for use in combination with oral anti-diabetes agents as a third-line pre-insulin treatment option. The SMC has not reviewed and does not recommend its use as monotherapy.

To read the SMC’s advice in full, visit the dulaglutide and albiglutide pages on its website.

Related content
;
Free for all UK & Ireland healthcare professionals

Sign up to all DiabetesontheNet journals

 

By clicking ‘Subscribe’, you are agreeing that DiabetesontheNet.com are able to email you periodic newsletters. You may unsubscribe from these at any time. Your info is safe with us and we will never sell or trade your details. For information please review our Privacy Policy.

DiabetesontheNet Logo

Are you a healthcare professional? This website is for healthcare professionals only. To continue, please confirm that you are a healthcare professional below.

We use cookies responsibly to ensure that we give you the best experience on our website. If you continue without changing your browser settings, we’ll assume that you are happy to receive all cookies on this website. Read about how we use cookies.